Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in South African Children: A Case-Control Study
This article, published in The Lancet Global Health, reports the results of a study that assessed the effectiveness of two or more doses of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children with HIV infection and in those not infected with HIV. The results indicated that PCV13 is effective for preventing vaccine-type pneumococcal infections in young children not infected with HIV as well as in children exposed to HIV but not infected and in malnourished children. The estimate for PCV13 effectiveness for children with HIV was high, but not statistically significant due to the small sample size. The findings suggest recommendations for widespread use of PCV in low- and middle-income countries.
Author: Cohen C, von Mollendorf C, de Gouveia L, et al.
» Visit web page (English)
(Located at www.thelancet.com)
Citation: Cohen C, von Mollendorf C, de Gouveia L, et al. Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in South African Children: A Case-Control Study. The Lancet Global Health. 2017;Early Online Publication.
Resource types: Peer-reviewed journal